
~~WHAT IS~~ CLAIM~~ED IS~~:

1. A compound of Formula (I)



(I),

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof,

wherein

X is independently selected from N or CH;


p is an integer selected from 1 or 2;

v is an integer selected from 1 or 2;

m is an integer selected from 1, 2, or 3;

n is an integer selected from 0, 1, or 2;

t is an integer selected from 1 or 2;

Ring A is  , wherein **2 refers to the position attached to phenyl;

Ring B is an aryl or 5- or 6- membered heteroaryl;

L^2 is a direct bond, $-(CR^aR^b)_q-$, -O-, -S-, -S(O)-, $-SO_2-$, -C(O)-, C(O)O-, -OC(O)-, $-NR^a-$, $-C(O)NR^a-$, $-NR^aC(O)-$, $-NR^aC(O)O-$, $-NR^aC(O)NR^b-$, $-SO_2NR^a-$, $-NR^aSO_2-$, $-NR^aS(O)_2NR^b-$, $-NR^aS(O)NR^b-$, $-C(O)NR^aSO_2-$, $-C(O)NR^aSO-$, $-C(=NR^a)NR^b-$, or cycloalkyl, wherein q is a number of 1 to 7;

R^{11} is $-C_{1-3}$alkyl, $-C_{3-10}$cycloalkyl, aryl, 5- or 6- membered monocyclic heteroaryl, 7- to 10-membered bicyclic heteroaryl, 3- to 6-membered monocyclic heterocyclyl, 7- to 14-membered bicyclic heterocyclyl, each of which is independently optionally substituted with 1, 2, 3 or 4 substituents R^{11X},

R^{11X}, at each occurrence, is independently halogen, $-C_{1-8}$alkyl, haloC_{1-8}alkyl, $-C_{2-8}$alkenyl, -

C_{2-8}alkynyl, -C_{3-8}cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO_2, -OR^{11a}, -SO_2R^{11a}, -COR^{11a}, -CO_2R^{11a}, -$CONR^{11a}R^{11b}$, -$C(=NR^{11a})NR^{11b}R^{11c}$, -$NR^{11a}R^{11b}$, -$NR^{11a}COR^{11b}$, -$NR^{11a}CONR^{11b}R^{11c}$, -$NR^{11a}CO_2R^{11b}$, -$NR^{1a}SONR^{11b}R^{11c}$, -$NR^{11a}SO_2NR^{11b}R^{11c}$, -$P(=O)R^{11a}R^{11b}$, or –$NR^{11a}SO_2R^{11b}$, wherein said C_{3-8}cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{1-8}alkoxyl, or -haloC_{1-8}alkoxyl;

R^{11a}, R^{11b}, and R^{11c} are each independently hydrogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, -C_{3-8}cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said C_{3-8}cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{1-8}alkoxyl, or -haloC_{1-8}alkoxyl;

R^{12} is hydrogen, halogen, -C_{1-8}alkyl, haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, -C_{3-8}cycloalkyl, heterocyclyl, aryl, heteroaryl, -oxo, -CN, -NO_2, -OR^{1a}, -SO_2R^{1a}, -COR^{1a}, -CO_2R^{1a}, -$CONR^{1a}R^{1b}$, -$C(=NR^{1a})NR^{1b}R^{1c}$, -$NR^{1a}R^{1b}$, -$NR^{1a}COR^{1b}$, -$NR^{1a}CONR^{1b}R^{1c}$, -$NR^{1a}CO_2R^{1b}$, -$NR^{1a}SONR^{1b}R^{1c}$, -$NR^{1a}SO_2NR^{1b}R^{1c}$, or –$NR^{1a}SO_2R^{1b}$;

R^{1a} and R^{1b}, are each independently hydrogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^{1c} is hydrogen, -C_{1-8}alkyl, -haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R^2 is independently selected from halogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl or -C_{3-6}cycloalkyl; wherein said -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl or -C_{3-6}cycloalkyl are each independently optionally substituted with halogen, hydroxy, C_{1-6}alkoxy, or amino, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, C_{3-6}cycloalkyl or C_{3-6}heterocyclyl;

R^3 is –L^1-CyC,

wherein

L^1 is a direct bond, -$(CR^aR^b)_{1-4}$-, -O-$(CR^aR^b)_{0-3}$-, -NH-$(CR^aR^b)_{1-3}$, -$NHC(O)NR^a$-$(CR^aR^b)_{1-3}$, or -NH-;

CyC is cycloalkyl, or heterocyclyl, each of which is optionally substituted with one, two, three or four substituents R^{3a};

R^{3a} is independently selected from hydrogen, halogen, cyano, oxo, -OR^{3b}, -$NR^{3b}R^{3c}$, -COR^{3b}, -SO_2R^{3b}, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, -cycloalkyl, or heterocyclyl, each of said -C_{1-8}alkyl, and heterocyclyl is optionally substituted with one, or two substituents R^{3e} which is selected from hydrogen, halogen, cyano, -OR^{3f}, -C_{1-8}alkyl, -cycloalkyl, or heterocyclyl;

wherein R^{3b}, and R^{3c} are each independently hydrogen, -C_{1-8}alkyl, -cycloalkyl, or heterocyclyl, said -C_{1-8}alkyl is optionally substituted with one or two substituents R^{5e} which is hydrogen, -$NR^{3f}R^{3g}$, -cycloalkyl, or heterocyclyl;

R^{3f} and R^{3g} are each independently hydrogen or -C_{1-8}alkyl;

or, two adjacent R^3 on the phenyl ring together with the phenyl ring form a benzo ring, said ring is optionally substituted with heteroaryl;

R^a and R^b are independently hydrogen, -C_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; and,

R^4 and R^5 are each independently hydrogen, halogen, cyano, $-NO_2$, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, or $-C_{2-8}$alkynyl.

2. The compound of claim 1, wherein X is N~~.~~; ring B is phenyl, furanyl, isoxazolyl, pyridinyl, pyrazolyl, or pyrimidinyl; wherein R^2 is halo, $-C_{1-6}$alkyl or $-C_{3-4}$cycloalkyl; wherein said $-C_{1-6}$alkyl and $-C_{3-4}$cycloalkyl are each independently optionally substituted with hydrogen, $-C_{1-3}$alkyl, C_{3-6}cycloalkyl or C_{3-6}heterocyclyl; and n is 0, and L^2 is $-(CH_2)_q-$, or -O-, wherein q is a number of 1-3.

~~**3.** The compound of claim 1, wherein ring B is phenyl, furanyl, isoxazolyl, pyridinyl, pyrazolyl, or pyrimidinyl.~~

~~**4.** The compound of claim 1, wherein R^2 is halo, C_{1-6}alkyl or C_{3-4}cycloalkyl; wherein said C_{1-6}alkyl and C_{3-4}cycloalkyl are each independently optionally substituted with hydrogen, C_{1-3}alkyl, C_{3-6}cycloalkyl or C_{3-6}heterocyclyl.~~

3~~5~~. The compound of claim 1, wherein R^2 is fluoro, methyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl or morpholinomethyl.

~~**6.** The compound of claim 1, wherein n is 0, and L^2 is $-(CH_2)_q-$, or -O-, wherein q is a number of 1-3, preferably 1.~~

4~~7~~. The compound of claim 1, wherein R^{11} is $-C_{3-10}$cycloalkyl, aryl, 5- or 6- membered monocyclic heteroaryl, 7- to 10-membered bicyclic heteroaryl, 3- to 6-membered monocyclic heterocyclyl, 7- to 14-membered bicyclic heterocyclyl, each of which is independently optionally substituted with 1, 2, or 3 substituents R^{11X}, wherein R^{11X} is defined as with formula (I).

5~~8~~. The compound of claim ~~7~~4, wherein –

a) R^{11} is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 3- to 6 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from oxygen and nitrogen atoms~~.~~; or

b) R^{11} is cyclohexyl, bicyclo[1.1.1]pentanyl, tetrahydro-2H-pyran-1-yl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl, tetrahydro-2H-pyran-4-yl oxazol-2-yl, oxazol-4-ylmethyl or oxazol-5-yl; or

c) R^{11} is phenyl or 8- to 10-membered bicyclic aryl, optionally substituted with 1 to 2 substituents R^{11X}; or

d) R^{11} is cyclohexyl, 4-methoxylcyclohexyl, bicyclo[1.1.1]pentan-1-yl, tetrahydro-2H-pyran-4-yl, oxazol-4-yl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 4-cyanophenyl, 4-methylphenyl, 4-(trifluoromethyl)phenyl, 2-methoxylphenyl, 3-methoxylphenyl, 4-methoxylphenyl, 4-ethoxylphenyl, 4-methoxylphenyl, 4-(trifluoromethoxyl)phenyl, 2,4-dimethoxylphenyl, 2,3-dimethoxylphenyl, 3,4-dimethoxylphenyl, 3,5-dimethoxylphenyl, 3,4,5-trimethoxylphenyl, chroman-6-yl, chroman-4-yl, 2,3-dihydrobenzo[b][1,4]dioxin-6-yl, 2,3-dihydrobenzo[b][1,4]dioxin-5-yl, or 5,6,7,8-tetrahydronaphthalen-2-yl, or 5,6,7,8-tetrahydronaphthalen-1-yl; or

e) R^{11} is furanyl, isoxazolyl, pyridinyl, pyrazolyl, pyrimidinyl, benzo[b]thiophenyl or benzofuranyl.

~~**9.** The compound of claim 7, wherein R^{11} is selected from cyclohexyl, bicyclo[1.1.1]pentanyl, tetrahydro-2H-pyran-1-yl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl, tetrahydro-2H-pyran-4-yl oxazol-2-yl, oxazol-4-ylmethyl or oxazol-5-yl.~~

~~**10.** The compound of claim 7, wherein R^{11} is selected from phenyl or 8- to 10-membered bicyclic aryl, optionally substituted with 1 to 2 substituents R^{11X}.~~

6~~11~~. The compound of claim 5~~10~~, wherein

(i) R^{11} is chromanyl, benzo[b][1,4]dioxinyl,5,6,7,8-tetrahydronaphthalenyl, octahydro-5H-2,5-methanoindenyl ~~(preferably octahydro-5H-2,5-methanoinden-5-yl)~~, 2,3,4,5-tetrahydrobenzo[b]oxepinyl ~~(preferably 2,3,4,5-tetrahydrobenzo[b]oxepin-7-yl)~~, adamantanyl ~~(preferably adamantan-1-yl)~~, each of which is optionally substituted with 1 or 2 R^{11X}; or~~.~~

(ii) R^{11} is furan-2-yl, isoxazol-4-yl, pyridin-3-yl, pyridin-2-yl, 1H-pyrazol-4-yl, pyrimidin-2-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-4-yl, benzofuran-5-yl, or benzofuran-4-yl; or

~~(ii)~~(iii) R^{11} is phenyl substituted with cyano, fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, difluoromethyl, trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetan-3-yl, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, $-NH_2$, or $-NH(CH_3)$.

7~~12~~. The compound of any one of claims 4~~7~~-11~~6~~, wherein R^{11X} is halogen, cyano, hydroxy, $-C_{1-8}$alkyl, haloC_{1-8}alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, C_{1-6}alkoxyl, haloC_{1-6}alkoxyl, C_{3-6}cycloalkyl, heterocyclyl, C_{3-6}cycloalkoxyl, $-NH_2$, $-NH(C_{1-8}$alkyl), $-N(C_{1-8}$alkyl$)_2$ or heterocyclyl-O-.

~~**13.** The compound of claim 10, wherein R^{11} is phenyl substituted with cyano, fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, difluoromethyl, trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetan-3-yl, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, $-NH_2$, or $-NH(CH_3)$.~~

~~**14.** The compound of claim 7, wherein R^{11} is cyclohexyl, 4-methoxylcyclohexyl, bicyclo[1.1.1]pentan-1-yl, tetrahydro-2H-pyran-4-yl, oxazol-4-yl, phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 4-cyanophenyl, 4-methylphenyl, 4-(trifluoromethyl)phenyl, 2-methoxylphenyl, 3-methoxylphenyl, 4-methoxylphenyl, 4-ethoxylphenyl, 4-methoxylphenyl, 4-(trifluoromethoxyl)phenyl, 2,4-dimethoxylphenyl, 2,3-dimethoxylphenyl, 3,4-dimethoxylphenyl, 3,5-dimethoxylphenyl, 3,4,5-trimethoxylphenyl, chroman-6-yl, chroman-4-yl, 2,3-dihydrobenzo[b][1,4]dioxin-6-yl, 2,3-dihydrobenzo[b][1,4]dioxin-5-yl, or 5,6,7,8-tetrahydronaphthalen-2-yl, or 5,6,7,8-tetrahydronaphthalen-1-yl.~~

~~**15.** The compound of claim 7, wherein R^{11} is furanyl, isoxazolyl, pyridinyl, pyrazolyl, pyrimidinyl, benzo[b]thiophenyl or benzofuranyl.~~

~~**16.** The compound of claim 15, wherein R^{11} is furan-2-yl, isoxazol-4-yl, pyridin-3-yl, pyridin-2-yl, 1H-pyrazol-4-yl, pyrimidin-2-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-4-yl, benzofuran-5-yl, or benzofuran-4-yl.~~

~~**17.** The compound of claim 7, wherein R^{11}-L^2- is selected from furan-2-ylmethyl, isoxazol-4-ylmethyl, (pyridin-3-yl)methyl, (6-methoxypyridin-3-yl)methyl, (5-methoxypyridin-2-yl)methyl, (1-methyl-1H-pyrazol-4-yl)methyl, (3-methoxy-1-methyl-1H-pyrazol-4-yl)methyl, (1-cyclopropyl-1H-pyrazol-4-yl)methyl, (5-methoxypyrimidin-2-yl)methyl, benzo[b]thiophen-5-ylmethyl, benzo[b]thiophen-4-ylmethyl, benzofuran-5-ylmethyl, or benzofuran-4-ylmethyl.~~

8~~18~~. The compound of claim 4~~7~~, wherein

a) R^{11}-L^2- is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or 1,2,3,4-tetrahydronaphthalen-1-yl, 3-phenylcyclobut-1-yl, 3-phenylcyclopent-1-yl, 4-phenylcyclohex-1-yl or 3-(4-methoxylphenyl)cyclopent-1-yl~~.~~; or

b) R^{11}-L^2- is a 3- to 6-membered monocyclic heterocyclyl selected from oxetanyl, tetrahydrofuranyl, or tetrahydro-2H-pyranyl; or


~~a)~~c) R^{11}-L^2- is selected from furan-2-ylmethyl, isoxazol-4-ylmethyl, (pyridin-3-yl)methyl, (6-methoxypyridin-3-yl)methyl, (5-methoxypyridin-2-yl)methyl, (1-methyl-1H-pyrazol-4-yl)methyl, (3-methoxy-1-methyl-1H-pyrazol-4-yl)methyl, (1-cyclopropyl-1H-pyrazol-4-yl)methyl, (5-methoxypyrimidin-2-yl)methyl, benzo[b]thiophen-5-ylmethyl, benzo[b]thiophen-4-ylmethyl, benzofuran-5-ylmethyl, or benzofuran-4-ylmethyl.

~~**19.** The compound of claim 7, wherein R^{11}-L^2- is a 3- to 6-membered monocyclic heterocyclyl selected from oxetanyl, tetrahydrofuranyl, or tetrahydro-2H-pyranyl, preferably oxetan-3-yl, tetrahydrofuran-3-yl, and tetrahydro-2H-pyran-4-yl.~~

9~~20~~. The compound of claim 1, wherein L^2 is $-SO_2-$ or -CO-, and R^{11} is $-C_{1-3}$alkyl or phenyl, each of which is optionally substituted with C_{1-3}alkoxyl.

10~~21~~. The compound of claim 1, wherein m is 1, R^3 is $-L^1$-CyC, and L^1 is a direct bond, $-(CH_2)_{0-2}-$, $-N(CH_2)_{0-2}$, or $-O(CH_2)_{0-2}$.

11~~22~~. The compound of claim 1, wherein CyC is

a) cycloalkyl selected from monocyclic C_{3-8}cycloalkyl or bridged cycloalkyl (), each of which is optionally substituted with one or two substituents R^{3a}~~.~~; or

b) heterocyclyl selected from monocyclic 4 to 9-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as ring member; monocyclic 4 to 9-membered heterocyclyl groups containing two heteroatoms selected from oxygen, sulfur, and nitrogen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

c) 5- to 10-membered spiro heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

d) 5- to 10-membered bridged heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

e) a monocyclic 6-membered heterocyclyl group containing two heteroatoms selected from oxygen and nitrogen as ring members; or

~~a)~~f) 4-membered/4-membered, 3-membered/5-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro heterocyclyl comprising one or two nitrogen or oxygen as ring members.

12~~23~~. The compound of claim 11~~22~~, wherein CyC is

(i) cyclobutyl, cyclopentyl or cyclohexyl, each of which is optionally substituted with one or two substituents R^{3a}; or

(ii) a monocyclic 4 to 6-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as the ring members; or

(iii) oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperdinyl;

(iv) dioxanyl, morpholino, morpholinyl, or piperzinyl; or

~~(i)~~(v) 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.

~~**24.** The compound of claim 1, wherein CyC is:~~

~~a) heterocyclyl selected from monocyclic 4 to 9 membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as ring member; monocyclic 4 to 9 membered heterocyclyl groups containing two heteroatoms selected from oxygen, sulfur, and nitrogen as ring members,~~

~~b) 5- to 10-membered spiro heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, or,~~

~~c) 5- to 10-membered bridged heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members;~~

~~each of which is optionally substituted with one, two, three or four substituents R^{3a}.~~

~~**25.** The compound of claim 24, wherein CyC is monocyclic 4 to 6 membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as the ring members.~~

~~**26.** The compound of claim 25, wherein Cyc is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperdinyl.~~


13~~27~~. The compound of claim ~~26~~12, wherein CyC is selected from oxetan-2-yl, Oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperdin-4-yl, piperdin-2-yl, and piperdin-3-yl.

~~**28.** The compound of claim 1, wherein CyC is a monocyclic 6 membered heterocyclyl group containing two heteroatoms selected from oxygen and nitrogen as ring members.~~

~~**29.** The compound of claim 28, wherein CyC is dioxanyl, morpholino, morpholinyl, or piperzinyl.~~

~~**30.** The compound of claim 28, wherein CyC is 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.~~

~~**31.** The compound of claim 1, wherein CyC is 4-membered/4-membered, 3-membered/5-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro heterocyclyl comprising one or two nitrogen or oxygen as ring members.~~

14~~32~~. The compound of claim 11~~2~~4, wherein CyC is  (7-oxa-2-azaspiro[3.5]nonan-2-yl), or  (2-oxaspiro[3.5]nonan-7-yl).

15~~33~~. The compound of claim 14~~32~~, wherein R^{3a} is independently selected from hydrogen, halogen, cyano, oxo, $-OR^{3b}$, $-NR^{3b}R^{3c}$, $-C(=O)R^{3b}$, $-SO_2R^{3b}$, $-C_{1\text{-}6}$alkyl, monocyclic $C_{3\text{-}6}$cycloalkyl, or monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members, each of said $-C_{1\text{-}6}$alkyl and monocyclic 4 to 9-membered heterocyclyl group is optionally substituted with one or two substituents R^{3e}.

16~~34~~. The compound of claim 15~~33~~, wherein ~~cycloalkyl as~~

a) R^{3a} is $C_{3\text{-}6}$cycloalkyl~~; more preferably cyclopropyl~~; or

b) R^{3a} is 4 to 6-membered heterocyclyl groups containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members; or

c) R^{3a} is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperzinyl, or morpholinyl; or

d) R^{3a} is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, or morphin-4-yl; or

e) R^{3e} is monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members; or

f) R^{3e} is tetrahydro-pyran-4-yl; or

g) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} is hydrogen, and R^{3c} is heterocyclyl; or

h) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} is hydrogen, and R^{3c} is tetrahydro-pyran-4-yl; or

i) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} and R^{3c} are each independently hydrogen or $-C_{1-6}$alkyl substituted with cycloalkyl; or

j) R^{3a} is $-OR^{3b}$ or $-SO_2R^{3b}$, wherein R^{3b} is hydrogen or C_{1-8}alkyl; or

~~a)~~k) R^{3a} is $-COR^{3b}$, wherein R^{3b} is hydrogen or C_{1-6}alkyl optionally substituted with $-NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} are each independently hydrogen or C_{1-6}alkyl.

~~**35.** The compound of claim 33, wherein heterocyclyl as R^{3a} is 4 to 6-membered heterocyclyl groups containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members.~~

~~**36.** The compound of claim 33, wherein heterocyclyl as R^{3a} is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperzinyl, or morpholinyl.~~

~~**37.** The compound of claim 33, wherein heterocyclyl as R^{3a} is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, or morphin-4-yl.~~

~~**38.** The compound of claim 33, wherein heterocyclyl as R^{3e} is monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members.~~

~~**39.** The compound of claim 33, wherein heterocyclyl as R^{3e} is tetrahydro-pyran-4-yl.~~

~~**40.** The compound of claim 33, wherein R^{3a} is $-NR^{3b}R^{3e}$, wherein R^{3b} is hydrogen, and R^{3e} is heterocyclyl.~~

~~**41.** The compound of claim 33, wherein R^{3a} is $-NR^{3b}R^{3e}$, wherein R^{3b} is hydrogen, and R^{3e} is tetrahydro-pyran-4-yl.~~

~~**42.** The compound of claim 33, wherein R^{3a} is $-NR^{3b}R^{3e}$, wherein R^{3b} and R^{3e} are each independently hydrogen or $-C_{1-6}$alkyl substituted with cycloalkyl, preferably $-C_{1-6}$alkyl substituted with monocyclic C_{3-6}cycloalkyl.~~

~~**43.** The compound of claim 33, wherein R^{3a} is $-OR^{3b}$ or $-SO_2R^{3b}$, wherein R^{3b} is hydrogen or C_{1-8}alkyl, preferably methyl.~~

~~**44.** The compound of claim 33, wherein R^{3a} is $-COR^{3b}$, wherein R^{3b} is hydrogen or C_{1-6}alkyl optionally substituted with $-NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} are each independently hydrogen or C_{1-6}alkyl, preferably methyl.~~

17~~45~~. The compound of any one of claims 1-16,

q is 1; or

R^{11} is octahydro-5H-2,5-methanoinden-5-yl, 2,3,4,5-tetrahydrobenzo[b]oxepin-7-yl, or adamantan-1-yl, or

R^{11}-L^2- is oxetan-3-yl, tetrahydrofuran-3-yl, and tetrahydro-2H-pyran-4-yl, or


R^{3a} is cyclopropyl, or -$NR^{3b}R^{3c}$, or


R^{3a} is -$NR^{3b}R^{3c}$, R^{3b} and R^{3c} are each independently hydrogen or–C_{1-6}alkyl substituted with monocyclic C_{3-6}cycloalkyl, or

R^{3a} is -COR^{3b}, wherein R^{3b} is hydrogen or C_{1-6}alkyl optionally substituted with -$NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} are each independently hydrogen or methyl.

18. The compound of claim 1, wherein two adjacent R^3 on the phenyl ring together with the phenyl ring form indazolyl which is substituted with tetrahydropyranyl.

1946. The compound of claim 1, wherein m is 1 and R^3 is selected from the group consisting of:







20~~47~~. The compound of claim 1, wherein R^4 is halogen selected from fluoro (-F), chloro (-Cl) or bromo (-Br)~~, preferably fluoro (-F)~~.

21~~48~~. The compound of claim 1, wherein R^4 is at position 3 of the pyrrolo[2,3-b]pyridin-5-yl ring.


22~~49~~. The compound of claim 1, wherein the compound is selected from the group consisting of~~the exemplified compounds~~:




(Ex. 2);




(Ex. 3a) and (Ex. 3b);




(Ex. 4);




(Ex. 5);




(Ex. 6);




or




(Ex. 6a) and (Ex. 6b);




(Ex. 7);




(Ex. 8);




(Ex. 9);




(Ex. 10);






(Ex. 11);





(Ex. 12);



(Ex. 13);



or

(Ex. 13a) and (Ex. 13b);



(Ex. 14);




(Ex. 15);




(Ex. 16);



(Ex. 17);



(Ex. 18);



(Ex. 19);



or

(Ex. 19a);


 or  (Ex. 19b);


 (Ex. 20);


 (Ex. 21);


 (Ex. 22);


 (Ex. 22a) and (Ex. 22b);


 (Ex. 23);

 (Ex. 24a) and (Ex. 24b);


 (Ex. 25a) and (Ex. 25b);

 (Ex. 26);


 (Ex. 27);




(Ex. 28);




or




(Ex. 28a);




(Ex. 29);




or




(Ex. 29a);




(Ex. 30);




(Ex. 31);




or




(Ex. 32);




or





(Ex. 33);





(Ex. 34);



(Ex. 35);



(Ex. 36);



(Ex. 37);



(Ex. 38);



(Ex. 39);



(Ex. 40);



(Ex. 41);



(Ex. 42);


(Ex. 43);



(Ex. 44);


(Ex. 45);



(Ex. 46);




(Ex. 47);




(Ex. 48);




or




(Ex. 48a);




(Ex. 49);




(Ex. 50);




(Ex. 51);




(Ex. 52);




or




(Ex. 52a);





(Ex. 53);





(Ex. 54);



(Ex. 55);



(Ex. 56);



(Ex. 57);



(Ex. 58);



(Ex. 59);



(Ex. 60);



(Ex. 61);



(Ex. 62);



(Ex. 63);




(Ex. 64a) and (Ex. 64b);



(Ex. 65);



(Ex. 66);



(Ex. 67);



(Ex. 68);



or

(Ex. 69);



(Ex. 70);



(Ex. 71);



(Ex. 72);



(Ex. 73);



(Ex. 74);



(Ex. 75);



(Ex. 76);



(Ex. 77);



(Ex. 78);



(Ex. 79);



(Ex. 79a);



(Ex. 79b);



(Ex. 80a) and (Ex. 80b);



(Ex. 81);


(Ex. 81a);



(Ex. 81b);


(Ex. 82);



(Ex. 83);




or




(Ex. 84);




or




(Ex. 85);




or




(Ex. 86);




or




(Ex. 87);




or




(Ex. 88);




or




(Ex. 89);




or




(Ex. 90);




or




(Ex. 91);




or




(Ex. 92);




or





(Ex. 93);





or





(Ex. 94);



or

(Ex. 95);



(Ex. 96);



(Ex. 97);



(Ex. 98);



(Ex. 99);



(Ex. 100);



(Ex. 101);



(Ex. 102);



(Ex. 103);



(Ex. 104);



(Ex. 105);



(Ex. 106);



(Ex. 107);



(Ex. 108);



(Ex. 109);



(Ex. 110), (Ex. 111) and (Ex. 112);



(Ex. 113);


(Ex. 114);



(Ex. 115);


(Ex. 116);



(Ex. 117);




(Ex. 118);




(Ex. 119);




(Ex. 120);




(Ex. 121);




(Ex. 121a);




(Ex. 122);




(Ex. 123);




(Ex. 124);




(Ex. 125);





(Ex. 126);





(Ex. 127);



(Ex. 128);



(Ex. 129);



(Ex. 130);



(Ex. 131);



(Ex. 132);



(Ex. 133);



(Ex. 134);



(Ex. 135);



(Ex. 136);



(Ex. 137);



(Ex. 138);



(Ex. 139);



(Ex. 140);



(Ex. 141a);



(Ex. 141b);



(Ex. 142);



(Ex. 143);



(Ex. 144);



(Ex. 145);



(Ex. 146);



(Ex. 147);



(Ex. 148);



(Ex. 149a);



(Ex. 149b);



(Ex. 150);



(Ex. 151);



(Ex. 152);



(Ex. 153);



(Ex. 154);



(Ex. 155);



(Ex. 156);



(Ex. 157);



(Ex. 158);



(Ex. 159);



(Ex. 160);



(Ex. 161);



(Ex. 162);



(Ex. 163);



(Ex. 164);



(Ex. 165);



(Ex. 166);



(Ex. 167);



(Ex. 168);



(Ex. 169);



(Ex. 170);



(Ex. 171);



(Ex. 172);



(Ex. 173);



(Ex. 174);



(Ex. 175);


(Ex. 176);



(Ex. 177);


(Ex. 178);



(Ex. 179);




(Ex. 180);




(Ex. 181);




(Ex. 182);




(Ex. 183);




(Ex. 184);




(Ex. 185);




(Ex. 186);




(Ex. 187);




(Ex. 188);




(Ex. 189);




(Ex. 190);




(Ex. 191);




(Ex. 192);




(Ex. 193);




(Ex. 194);




(Ex. 195);




(Ex. 196);




(Ex. 197);




(Ex. 198);




(Ex. 199);




(Ex. 200);




(Ex. 201);




(Ex. 202);




(Ex. 203);




(Ex. 204);




(Ex. 205);




(Ex. 206);




(Ex. 207);




(Ex. 208);




(Ex. 209);




(Ex. 210);





(Ex. 211);





(Ex. 212);



(Ex. 213);



(Ex. 214);



(Ex. 215);



(Ex. 216);



(Ex. 217);



(Ex. 218);



(Ex. 219);



(Ex. 220);



(Ex. 221);



(Ex. 222);



(Ex. 223);



(Ex. 224);



(Ex. 225) and (Ex. 226);



(Ex. 227);



(Ex. 228);



(Ex. 229);



(Ex. 230);



(Ex. 231);


(Ex. 232);



(Ex. 233);


(Ex. 234);



(Ex. 235);




(Ex. 236) and (Ex. 237);




(Ex. 238);




(Ex. 239);




(Ex. 240);




(Ex. 241);




(Ex. 242);




(Ex. 243);




(Ex. 244);




(Ex. 245);





(Ex. 246);





(Ex. 247);



(Ex. 248);



(Ex. 249);



(Ex. 250);



(Ex. 251);



(Ex. 252);



(Ex. 253);



(Ex. 254);



(Ex. 255);



(Ex. 256);



(Ex. 257);



(Ex. 258);



(Ex. 259);



(Ex. 260);



(Ex. 261);



(Ex. 262);



(Ex. 263);



(Ex. 264);



(Ex. 265);


(Ex. 266);



(Ex. 267);


(Ex. 268);



(Ex. 269);




(Ex. 270);




(Ex. 271);




(Ex. 272);




(Ex. 273);




(Ex. 274);




(Ex. 275);




(Ex. 276);




(Ex. 277);




(Ex. 278);





(Ex. 279);





(Ex. 280);



(Ex. 281);



(Ex. 282);



(Ex. 283);



(Ex. 284);



(Ex. 285);



(Ex. 286);



(Ex. 287);



(Ex. 288);



(Ex. 289);



(Ex. 290);



(Ex. 291);



(Ex. 292);



(Ex. 293);



(Ex. 294);



(Ex. 295);



(Ex. 296);



(Ex. 297);



(Ex. 298);


(Ex. 299);



(Ex. 300);


(Ex. 301);



(Ex. 302);




(Ex. 303);




(Ex. 304);




(Ex. 305);




(Ex. 306);




(Ex. 307);




(Ex. 308);




(Ex. 309);




(Ex. 310);




(Ex. 311);




(Ex. 312);




(Ex. 313);




(Ex. 314);




(Ex. 315);




(Ex. 316);




(Ex. 317);




(Ex. 318);




(Ex. 319);




(Ex. 320);




(Ex. 321);




(Ex. 322);





(Ex. 323);





(Ex. 324);



(Ex. 325);



(Ex. 326);



(Ex. 327);



(Ex. 328);



(Ex. 329);



(Ex. 330);



(Ex. 331);



(Ex. 332);



(Ex. 333);



(Ex. 334);



(Ex. 335);



(Ex. 336);



(Ex. 337);



(Ex. 338);



(Ex. 339);



(Ex. 340);



(Ex. 341);



(Ex. 342);



(Ex. 343);



(Ex. 344);



(Ex. 345);



(Ex. 346);



(Ex. 347);



(Ex. 348);



(Ex. 349);



(Ex. 350);



(Ex. 351);



(Ex. 352);


(Ex. 353);



(Ex. 354);


(Ex. 355);



(Ex. 356);




(Ex. 357);




(Ex. 358);




(Ex. 359);




(Ex. 360);




(Ex. 361);




(Ex. 362);




(Ex. 363);




(Ex. 364);





(Ex. 365);





(Ex. 366);


(Ex. 367);


(Ex. 368);


(Ex. 369);


(Ex. 370); or


(Ex. 371).

2350. A pharmaceutical composition, comprising the compound of any one of claims 1-2249 or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and at least one of pharmaceutically acceptable excipients.

2451. Use of the compound of any one of claims 1-2349, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof in the manufacture of a medicament ~~A method~~ for treating dysregulated apoptotic diseases~~, comprising administering a subject in need thereof a therapeutically effective amount of the compound of any one of claims 1-49, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof~~.

2552. The use~~method~~ of claim 2451, wherein the dysregulated apoptotic disease is a neurodegenerative condition, proliferative diseases, and pro-thrombotic conditions.